247 related articles for article (PubMed ID: 26378038)
1. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
[TBL] [Abstract][Full Text] [Related]
2. BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.
Kokkola T; Suuronen T; Pesonen M; Filippakopoulos P; Salminen A; Jarho EM; Lahtela-Kakkonen M
Chembiochem; 2015 Sep; 16(14):1997-2001. PubMed ID: 26212199
[TBL] [Abstract][Full Text] [Related]
3. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
[TBL] [Abstract][Full Text] [Related]
5. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
[TBL] [Abstract][Full Text] [Related]
6. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
7. BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells.
Alghamdi S; Khan I; Beeravolu N; McKee C; Thibodeau B; Wilson G; Chaudhry GR
Stem Cell Res Ther; 2016 Feb; 7():22. PubMed ID: 26830473
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
[TBL] [Abstract][Full Text] [Related]
10. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
11. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of BDNF Expression and Memory by HDAC Inhibition Requires BET Bromodomain Reader Proteins.
Sartor GC; Malvezzi AM; Kumar A; Andrade NS; Wiedner HJ; Vilca SJ; Janczura KJ; Bagheri A; Al-Ali H; Powell SK; Brown PT; Volmar CH; Foster TC; Zeier Z; Wahlestedt C
J Neurosci; 2019 Jan; 39(4):612-626. PubMed ID: 30504275
[TBL] [Abstract][Full Text] [Related]
13. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
[TBL] [Abstract][Full Text] [Related]
14. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.
Kumar K; DeCant BT; Grippo PJ; Hwang RF; Bentrem DJ; Ebine K; Munshi HG
JCI Insight; 2017 Feb; 2(3):e88032. PubMed ID: 28194432
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.
Sengupta S; Biarnes MC; Clarke R; Jordan VC
Breast Cancer Res Treat; 2015 Apr; 150(2):265-78. PubMed ID: 25721606
[TBL] [Abstract][Full Text] [Related]
16. BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.
Andrieu GP; Denis GV
Mol Cancer Res; 2018 Apr; 16(4):580-586. PubMed ID: 29437854
[TBL] [Abstract][Full Text] [Related]
17. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.
Pérez-Peña J; Győrffy B; Amir E; Pandiella A; Ocaña A
Breast Cancer Res Treat; 2018 Dec; 172(3):725-732. PubMed ID: 30206781
[TBL] [Abstract][Full Text] [Related]
19. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells.
Kapp N; Stander XX; Stander BA
Anticancer Drugs; 2018 Jun; 29(5):429-439. PubMed ID: 29561307
[TBL] [Abstract][Full Text] [Related]
20. Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.
Rajendran P; Johnson G; Li L; Chen YS; Dashwood M; Nguyen N; Ulusan A; Ertem F; Zhang M; Li J; Sun D; Huang Y; Wang S; Leung HC; Lieberman D; Beaver L; Ho E; Bedford M; Chang K; Vilar E; Dashwood R
Cancer Res; 2019 Mar; 79(5):918-927. PubMed ID: 30643017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]